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1 Study overview 
This meta-analysis study of educational attainment (EA) and cytosine-phosphate-guanine 
(CpG) methylation in human DNA was performed according to a pre-specified analysis plan. 
The analysis plan was publicly archived on Open Science Framework (OSF) in September 
2015 (available at https://osf.io/9v3nk/), and it specified two main analyses to be conducted 
at the cohort level – an epigenome-wide association study (EWAS)1, and an epigenetic clock 
analysis2. The EWAS is considered hypothesis-free as it is performed genome-wide without 
an expected direction of effect for individual CpG loci (often referred to as CpG probes), 
while the epigenetic clock analysis is hypothesis-driven since we a priori expect lower EA to 
be associated with a faster running epigenetic clock (a higher DNA methylation age). The 
methods of the EWAS and the epigenetic clock are further explained in 2. Epigenome-wide 
association study (EWAS) and 3. Epigenetic clock analyses. 
When we designed the study we aimed to achieve a sample size of at least 10,000 
individuals, which would lead to 80% power to detect an effect as small as R2 = 0.38%. This 
effect size is much smaller than those found in EWAS of other traits3–5, but smaller effect 
sizes could possibly be expected as EA is a biologically distal environmental factor. To 
achieve the desired sample size we were required to pool data across cohort studies and 
perform a meta-analysis. Due to privacy and data sharing restrictions the EWAS and 
epigenetic clock analysis could only be performed locally, and subsequently meta-analysed. 
Cohorts could join this study by providing a signed collaboration agreement and sample 
descriptives during the fall of 2015. The Principal Investigator (PI) of each cohort affirmed 
that the results contributed to the study were based on analyses approved by the local 
Research Ethics Committee and/or Institutional Review Board responsible for overseeing 
research. All participants provided written informed consent. An overview of the 27 
independent cohort studies from the 15 participating cohorts is reported in Supplementary 
Table S1.1. 
In summary, the EWAS was performed with a basic model with covariates for age, sex and 
white blood-cell counts, and an adjusted model with additional covariates to correct for the 
two lifestyle factors body mass index (BMI) and smoking, which were available in all 
cohorts. For a full description of the control variables see Supplementary Note 2.1.1. Since 
lifestyle factors such as BMI and smoking are known to be strongly associated with both 
methylation and EA6–8, we focus the presentation and follow-up analyses on the results of the 
adjusted model as we consider this to be more conservative. 
1.1 Sample inclusion criteria 
The analysis plan specified the individual inclusion criteria, limiting the analysis to 
individuals of European ancestry, who were at least 25 years of age at the time of assessment 
of EA. Individuals were to be excluded if they were cases from cohorts with a case-control 
study design; if they did not have successfully measured methylation or did not pass other 
cohort-specific standard quality control (QC) filters. Cohort-level individual and CpG probe 
filtering is explained in 1.3 DNA methylation measurement and cohort-level quality 
control (QC). A second quality control was implemented after meta-analysis, and this 
procedure is described in 2.2 Description of major steps in meta-level quality-control 
(QC) analyses. 
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The total meta-analysis sample sizes of the basic and adjusted EWAS models are respectively 
10,767, and 10,317. Some individuals were excluded from the adjusted model due to missing 
covariates, which caused the difference in sample size.  
Cohorts performed the analyses with code pre-specified in the analysis plan9, and this code 
can be accessed at Open Science Frameworka. For the EWAS the cohorts provided the 
following summary statistics for each probe to the meta-level analysis - CpG probe ID 
(markername), estimated regression coefficient (beta), standard error of the coefficient 
estimate, P-value of the coefficient estimate, and sample size. For the epigenetic clock 
analyses the cohorts provided the parameter estimates for the four different age acceleration 
measures, standard error of the parameter estimate, P-value of the parameter estimate, and 
sample size.  
1.2 Phenotype definition and sample descriptive statistics 
Educational attainment (EA) was harmonized across cohorts in accordance with earlier work 
of the Social Science Genetics Association Consortium (SSGAC)10,11, i.e., in accordance with 
the ISCED 1997 classification (UNESCO)12. The classification consists of seven 
internationally comparable categories, which were subsequently translated into US years-of-
schooling equivalents, which have a quantitative interpretation (Supplementary Table S1.2). 
The translated measure maintains a high level of variance in the phenotype and the cohort-
specific translation is reported in Supplementary Table S1.3, together with the within-
cohort means and standard deviations. 
A summary of the 27 independent cohort studies from the 15 contributing cohorts is reported 
in Supplementary Table S1.1. The within-cohort mean age at reporting ranges ranges from 
26.6 to 79.1 years, and the minimum and maximum age is respectively 18b and 94 years. The 
sample size ranges from 48 to 1,658, with an average of 399 individuals. The average EA 
within the cohorts ranges from 8.6 to 18.3 years of education, and the sample-size weighted 
average is 13.6 (SD = 3.62). Females comprise 54.1% of the meta-analysis sample.  
1.3 DNA methylation measurement and cohort-level quality control 
(QC) 
Genome-wide CpG methylation was measured in whole blood with the Illumina 450k Human 
Methylation chip. Since background correction and normalisation of methylation data is 
time-consuming and dependent on sample-specific properties, and as no method is 
considered overall superior, we encouraged the cohorts to perform background correction13 
and normalization14 according to their standard QC protocols to prepare the chip data for 
analyses. We report the cohort-specific technical details in Supplementary Table S1.4. 
Cohorts were recommended to implement exclusions of CpG probes and samples of 
individual participants using the following thresholds: probes should be excluded if the 
probe-detection P-value was greater than 0.01 in more than 5% of the individuals, and 
individuals should be excluded if the detection P-value was greater than 0.01 for more than 
5% of the probes within an individual. 
                                                            
a To access the code for follow-up analyses please contact the corresponding author. 
b The FTC and LLD cohorts were allowed to additionally include individuals slightly below 25 years of age 
because the FTC cohort includes on-going education in the EA measurement, and the cohorts has validated the 
phenotype with later cohort waves (Cohen’s κ = 0.82). The LLD cohort measures EA with high enough 
precision to capture most of the variation even for individuals that had not yet begun higher education. 
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White blood cell counts, which were included as covariates to avoid confounding due to 
differential leukocyte cell composition across individuals, could either be measured directly 
or imputed based on the Houseman algorithm15. 
To summarize, we standardized the analysis protocol as much as possible, while ensuring 
some degree of flexibility to keep the implementation feasible for all samples. 
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2 Epigenome-wide association study (EWAS) 
The dependent variable in the epigenome-wide association study (EWAS) was the 
methylation beta-value, i.e., the proportion of methylation at a CpG locus across the 
measured cells within an individual. The beta-value hence lies in the interval [0, 1], and has a 
biologically meaningful interpretation. An alternative approach is to regress the methylation 
as the so-called M-value, which is the log2 transformed beta-value16. For comparability, we 
used the beta-values following the methodology of the largest EWAS studies to our 
knowledge3,5,6,17. The relation between CpG methylation and the technical covariates 
motivates having the methylation as the dependent variable since the technical covariates 
reduce the error variance leading to greater statistical power to find associations with the 
phenotype of interest. 
Each cohort study performed estimated the following regression for each CpG probe passing 
cohort-level quality control: 
(1) 𝐶𝑝𝐺! = 𝛽! + 𝛽!𝐸𝐴! + 𝑷𝑪𝒊𝜸+ 𝑿𝒊𝜶+ 𝑪𝒊𝜽+ 𝜖! , 
where 𝐶𝑝𝐺! is the methylation beta-value for individual i, 𝐸𝐴! is the harmonized continuous 
measure of EA, 𝑷𝑪𝒊 is a vector of the first four principal components of the genetic 
relatedness matrix, and 𝑿𝒊 is a vector of control variables further explained below. 𝑪𝒊 is a 
vector containing study-specific controls and technical covariates (such as dummy variables 
for plates, hybridisation date, and batches) that were encouraged in the analysis plan and 
discussed below.  
In accordance with the pre-specified analysis plan, probes with P-value less than 1×10–7 (the 
commonly-used threshold in epigenome-wide association studies1) were considered as 
epigenome-wide significant associations. We report two-tailed P-values throughout the paper 
unless otherwise specified. 
2.1.1 Control variables in the adjusted model 
Two epigenome-wide association analyses were performed in each cohort, a basic model and 
an adjusted model. The two models differ in the included covariates (𝑿𝒊) in accordance with 
the pre-specified analysis plan, where the basic model controls for age, sex, and white blood-
cell counts. The adjusted model additionally includes BMI (kg/m2), and smoking measured as 
a categorical variable (measured either as Ever/Never smoker or Current/Former/Never 
smoker, depending on data availability), together with a squared age term to account for non-
linear age effects, and an interaction term between age and sex. Since lifestyle factors such as 
BMI and smoking are known to be strongly associated with both methylation and EA6–8, we 
focus the article on the results of the adjusted model as we consider this to be more 
conservative. 
The quadratic age term and the interaction between age and sex were added to the adjusted 
model, because of the known non-linear relationship between age and CpG methylation (see 
Bollati et al., 2009; Langevin et al., 2011; Horvath et al., 2012; Bell et al., 2013; Florath et 
al., 2014)18–22, as well as the relationship between sex and CpG methylation (e.g. Boks et al., 
2009; Liu et al., 2010; Zhang et al. 2011)23–25. Moreover, levels of educational attainment 
(our main explanatory variable) vary by age (birthyear) and sex (see e.g. Barro and Lee, 
2001)26. Hence, the inclusion of these control variables is both biologically and statistically 
warranted.  
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2.1.2 Cohort-specific control variables 
After discussion with the meta-analysts a few additional cohort-specific control variables 
were encouraged if they were deemed necessary to control for confounding relationships 
between EA and CpG methylation, and these cohort-specific control variables were included 
in 𝑪𝒊. The EPIC and MCCS cohorts did not have genetic data available to allow inclusion of 
genetic PCs, so the first principal component of the methylation matrix was included instead 
as a stringent alternative to control for possible inflation of the test statistic due to subtle 
population stratification. The HBCS cohort included a dummy for childhood separation 
exposure, KORA F4 a dummy for World War 2, and MCSS included country of birth control 
variables, all of which could plausibly be correlated with both EA and methylation. 
Moreover, in ALSPAC, EPIC-Breast Cancer, MCCS-Breast Cancer, and MCCS-Prostate 
Cancer, sex was not included because these samples consist of solely females or males. In 
EGCUT1 smoking was not included because all participants were non-smokers. The EPIC 
and MCSS samples did not control for genetic PCs because of unavailability of these 
variables but controlled instead for the first PC of the methylation data as a stringent 
alternative. The age2 term was not included in the LBC models due to the very narrow age-
range in these birth cohort samples. 
2.2 Description of major steps in meta-level quality-control (QC) 
analyses 
A stringent quality-control (QC) protocol was performed to ensure that only high-quality 
CpG probes were meta-analysed. All cohorts were asked to supply descriptive statistics and 
phenotype definitions according to the pre-specified analysis plan, and the completeness of 
these documents was assessed as the first step of quality control, together with examination 
of the uploaded EWAS summary statistics. Thereafter we applied the following probe filters. 
Filters were applied to remove probes with missing P-value, standard error or coefficient 
estimate; probes not available in the probe annotation reference by Price et al. (2013)27; CpH 
probes (H = A/C/T); probes on the sex chromosomes; cross-reactive probes highlighted in a 
recent paper by Chen et al.28; and probes with a cohort-level call rate less than 95%.  
Probes were annotated if they were so-called SNP-probes, i.e., if the probe is located on a 
single-nucleotide polymorphism (SNP). This was done so that any positive results could be 
interpreted with caution if the associated probe would be located on a SNP, as this is known 
to affect the methylation status of the CpG probe27. We however chose to keep all SNP-
probes in the results, rather than removing all of them. 
The output from the quality control was examined to see if any filters removed an unusual or 
unexpected number of probes, and two analysts independently performed and crosschecked 
the QC. After probe filtering, the distributions of the coefficient estimates (betas) were 
compared across the cohorts to identify possible outliers and birth-year effects. 
2.3 Meta-analysis 
Due to the differences in the mean and standard deviation of CpG methylation across cohorts 
we decided to perform sample-size weighted fixed-effect meta-analysis of the cohort-level 
EWAS summary statistics using the METAL29 software, as fixed effect meta-analysis is 
robust to differences in units of measurement. Due to the variability of 𝜆!"  across cohorts we 
applied cohort-level genomic control to deflate the association test statistic prior to meta-
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analysis, equivalent to its GWAS analogue30, to stringently control for possible population 
stratification that could remain even after controlling for genetic principal components in 
regression. In the final meta-analysis results, only probes with a meta-level sample size 
greater than 1,000 were considered. 
2.4 Results – Epigenome-wide association study 
2.4.1 Quality control results 
The result of the quality-control filtering is reported in Supplementary Table S1.5 where we 
also report the post-QC cohort-level genomic inflation factor, 𝜆!" , which we define here as 
its GWAS analogue31, i.e., as the ratio of the median of the empirically observed distribution 
of the chi-square test statistic to the expected median of the null distribution. 
After quality control, the remaining probes were used to produce quantile-quantile (QQ) plots 
for visual inspection. Most cohorts showed no sign of inflation of the association test 
statistics, while the cohorts LLD, MCCS lung, and RS3 displayed some inflation among 
probes with P-values above 0.05, and a few other cohorts instead displayed deflation. 
Inflation can be expected if a probe is associated by chance in a cohort due to the correlation 
between the chance finding and other probes32, as well as if the trait is truly associated with 
many probes, similar to the effect on 𝜆!"  caused by polygenicity in GWAS30. Compared to 
other EWAS of similar sample size4, we also noticed some variability in the 𝜆!"  between 
cohorts, and the average 𝜆!"  of the adjusted model was 1.022 (SD = 0.175). For stringency 
we applied genomic control deflation of the test statistics of each cohort prior to meta-
analysis32, which is further explained in section 2.3 Meta-analysis. After genomic control the 
meta-analysis 𝜆!"  is 1.195 for the basic model, and 1.061 for the adjusted model. 
We analysed the heterogeneity of effect-size directions across the cohort studies to detect 
possible outliers. We report the cohort-level direction of effects in Supplementary Table 
S1.6a and Supplementary Table S1.7a. To probe the validity of using OLS in the EWAS, 
we inspected the distribution of the beta values for the lead probes and verified that the 
distribution of the error term in the adjusted model of these probes was (approximately) 
normal. 
2.4.1 EWAS results 
Manhattan plots and QQ-plots of the meta-analysis of the basic model and the adjusted model 
are presented in Supplementary Figure 1 and 2. There were 37 CpG probes associated with 
EA at epigenome-wide significance threshold (P < 10–7) in the basic model, the results are 
reported in Supplementary Table S1.6a, and 9 probes were found to be associated in the 
adjusted model (all of which were associated in the basic model). The 9 associated probes 
from the adjusted model are listed in Supplementary Table S1.7a, and we hereafter refer to 
these 9 as the lead probes.  
We note that based on physical position, three lead probes are located within a 1kb window 
on chromosome 2, two lead probes are within 26kb on chromosome 5, and two lead probes 
are within 0.5kb on chromosome 7. If we prune the lead probes by keeping the strongest 
association within a 250kb window, then there are five “approximately independent” lead 
probes. Even though the independence of these associations is not certain due to their 
proximity, we choose to display all of the 9 associated probes as is customary in the EWAS 
literature. 
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2.4.1 Benjamini-Hochberg correction 
As an alternative to the stringent epigenome-wide significance threshold (P < 10–7), we 
investigated the False Discovery Rate (FDR) as is common in the EWAS literature. FDR-
controlling procedures are used to control the expected proportion of rejected null hypotheses 
that are incorrect rejections. As our analysis plan did not specify that an FDR-correction 
would be applied, we present this for completeness with the EWAS literature but do not 
focus on the individual probesc. Hence, if we instead used a Benjamini-Hochberg FDR 
threshold of 0.05, then there would be 364 probes passing the threshold for the basic model, 
and 26 for the adjusted model Supplementary Table S1.6b and Supplementary Table 
S1.7b33.  
2.4.2 Comparison of EWAS effect-sizes with other phenotypes 
In Figure 2 and Supplementary Table S1.8 we present the effect-size estimates, in terms of 
R2, of the 50 most associated probes of our adjusted EWAS model. For comparison we 
contrast the results with the 50 most associated probes from recent, large-scale EWAS on 
alcohol consumption (n = 9,643, Liu et al., 2016)17, BMI (n = 7,798, Mendelson et al., 
2017)3, smoking (n = 9,389, Joehanes et al., 2016)6, and maternal smoking (n = 6,685, 
Joubert et al., 2016)4, and as a comparison between EWAS and GWAS we also display the 
top 50 “approximately independent” SNPs from a large (n  = 405,073), and recent GWAS 
meta-analysis of educational attainment by Okbay et al. (2016)34.  
Noticeable is the large difference between the strong effects of smoking (largest R2 = 2.2%) 
and maternal smoking (largest R2 = 11.6%), in comparison with our EWAS results (largest R2 
= 0.69%). Also the effects of BMI on methylation are consistently stronger than those of EA, 
while the effects of alcohol consumption are more similar, but still consistently larger than 
those of EA. There are also large differences between EWAS and GWAS of EA, where the 
SNP effects are an order of magnitude smaller than the CpG probe effect sizes. 
                                                            
c Many of the follow-up analyses include probes from the adjusted model with P-value less than 1×10–4 or 1×10–
5, and these analyses therefore include more information than just the associations of the 9 lead probes. 
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3  Epigenetic clock analyses 
The association between EA and biological ageing was examined with an epigenetic clock 
analysis2. A priori, we hypothesised that lower EA would be associated with a faster rate of 
ageing, resulting in a faster running epigenetic clock. The epigenetic age was assessed 
according to the specified analysis protocol by entering raw CpG beta value data into the 
online Horvath calculatord. The "normalize data" and "advanced analysis for Blood Data" 
options were selected. The following biological clock variables were selected from the 
calculator's output for downstream analysis:  
 1) Horvath age acceleration residuals (Clock 1), which are the residuals from the 
regression of chronological age on Horvath age. 
 2) White blood cell count adjusted Horvath age acceleration (Clock 2), which is the 
residual from (1) after additional covariate adjustment for imputed white blood cell counts. 
 3) White blood cell count adjusted Hannum age acceleration (Clock 3), which is the 
same as (2) but with the Hannum age prediction in place of the Horvath prediction. 
 4). Cell-count enriched Hannum age acceleration (Clock 4), which is the basic 
Hannum predictor plus a weighted average of ageing associated cell counts. This index has 
been found to give the strongest association between epigenetic age acceleration and 
mortality35. 
Linear regression was used to test the associations between education and the four selected 
measures of DNA methylation age acceleration. Two models were considered for each age 
acceleration measure: adjustment for age and sex (basic age acceleration model), and 
additional control variables for body mass index and smoking (adjusted age acceleration 
model). Sample-size weighted meta-analyses of the results were performed across cohorts. 
3.1 Results – Epigenetic clock analyses 
The results of the epigenetic clock analyses are presented in Supplementary Table S1.9 and 
Figure 4. For the epigenetic clock analyses, the cohorts BSGS (only included in the basic 
model because of absent covariates for the adjusted model), FINRISK, and MCCS could not 
contribute. Therefore, the sample size for the basic age acceleration model was 8,173, and 
was 7,691 for the adjusted age acceleration model. We did not observe evidence of an 
association between EA and the epigenetic clock for Clock 1 (Horvath age acceleration 
residuals), Clock 2 (White blood cell count adjusted Horvath age acceleration), and Clock 3 
(White blood cell count adjusted Hannum age acceleration). We found evidence for an 
association between EA and Clock 4 (Cell-count enriched Hannum age acceleration, P = 
3.51×10–6 in the basic age acceleration model and P = 4.51×10–4 in the adjusted age 
acceleration model). We note that this latter measure (Hannum age acceleration with dynamic 
weights) is also the most predictive epigenetic clock measure of mortality35. Due to the 
inconsistent results across the different clock variables and the small estimated effect sizes, 
we refrain from drawing strong conclusion based on the epigenetic clock results. 
                                                            
d The Horvath calculator can be accessed at https://labs.genetics.ucla.edu/horvath/dnamage/. 
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4 Investigation of possible confounding with tobacco smoking 
The adjusted EWAS model included a categorical control variable for tobacco smoking 
(categorised as current, former or never smoker). Due to the discrete nature of the variable 
and the measurement error that follows by not measuring tobacco smoking as a continuous 
variable, we believe that the control variable might not have completely controlled for the 
exact smoking exposure. Unfortunately, controlling for smoking with a categorical variable is 
the common approach due to the lack of a more precise smoking measure in most cohort 
studies. As a result, smoking could potentially bias the regression coefficient of EA because 
of the known negative correlation between smoking and EA36, and the strong association 
between smoking and methylation found in a large number of studies4,6. Therefore, we 
performed a literature review using PubMed to see if any of the lead probes from the adjusted 
model have been associated with smoking in previous studies. 
The literature review was performed February 24, 2016 by searching for the term “smoking” 
together with each of the adjusted model’s 9 lead probes separately. The search resulted in 30 
eligible studies or smaller meta-analyses (n < 1,800) on CpG methylation and different forms 
of smoking exposure, one systematic review by Gao et al. (2015)37, and two larger meta-
analysis by Joehanes et al. (2016, n = 9,389)6 and Joubert et al. (2016, n = 6,685)4 that 
include many of the individual studies. The EWAS meta-analysis by Joehanes et al., 20166, 
comprising of several of the 30 individual studies, was published after the literature review 
had been performed and we added this study to the literature review post-hoc due to its 
relevance and large sample size. The result of the literature review is presented in 
Supplementary Table S.1.10.  
The studies could be categorised as investigating either the relationship between a person’s 
own smoking and methylation, or the association between newborn’s methylation and 
maternal smoking, both at birth and at later stages in the life of the offspring. Most of the 
individual studies have relatively small sample sizes (smallest sample size consists of only 21 
monozygotic twin pairs, and the average sample size is 471), and we note that many of the 
individual studies on personal smoking are meta-analysed in Joehanes et al. (2016), and most 
of the individual studies on maternal smoking are meta-analysed in Joubert et al. (2016).  
We found that all of the adjusted model’s 9 lead probes have been associated with smoking in 
at least one previous study, and in Supplementary Note 4.3 we contrast the EWAS effect 
sizes estimates for EA with the effect size estimates from the two meta-analyses studies. 
However, not all of these previous studies controlled for EA, and the associations between 
smoking and methylation could therefore be biased due to the non-inclusion of EA as a 
control variable, and this makes it complicated to draw definite conclusions of the magnitude 
of confounding. Also, the sample sizes of many of the individual studies are small and likely 
to contain a higher number of false positives than the meta-analyses.  
In light of this finding we interpret our EWAS findings carefully, and the literature review 
motivated the post-hoc sensitivity analyses in the subsample of people that never smoked 
presented in the next section. 
4.1 Robustness of EWAS results in the never-smoker subsample 
To further investigate the possible confounding effect of smoking on the association between 
EA and CpG methylation, all cohorts reran the EWAS in the subsample of individuals that 
reported as ‘never smoker’. We refer to this subsample as the never smokers. The full EWAS 
sample consists of the ever smokers (i.e., the individuals who answered that they were ever, 
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current, or former smokers), and the never smokers. This approach would give us confidence 
in the associations of the adjusted model if the lead probes were found to be associated with 
EA in the never-smoker subsample. We note that this sample could be biased in other ways 
when selected on this specific variable, and the statistical power will be lower due to the 
decrease in sample size, and we therefore do not perform any analyses of any other probes 
than the 9 lead probes in this subset. 
The meta-analysis sample size of the never-smoker subsample was 5,175, and with the effect 
size estimates from the adjusted model we calculated the power to find the effects in the 
never-smoker subsample. The expected power ranged from 6.4% to 74% (Supplementary 
Table S1.7a), at P-value < 10–7, and the expected number of replications was 1.93 given the 
expected power. If a more liberal Bonferroni-corrected threshold would be used, such as 0.05 
divided by 9, then the power in the never smokers ranged from 81% to 100%. Hence, we 
expected considerable statistical power to replicate the lead probes of the adjusted model in 
the never-smoker subsample assuming the full sample effect size estimates. 
After quality control, we performed a meta-analysis of the re-estimation in the never-smoker 
subsample, and the results are displayed in Supplementary Table S1.7a. None of the 9 lead 
probes were significant at the stringent epigenome-wide threshold of P < 10–7, while 2 
probes, cg12803068 and cg22132788, were estimated with strong associations even though 
the sample size was halved (with respective P-values 1.48×10–4 and 4.35×10–4). 
4.2 Joint test of no association in the never-smoker subsample 
We thereafter performed a joint test of the null hypothesis that the regression coefficients of 
the lead probes were all equal to zero, with the sample-size weighted Z-statistic estimated in 
the never smokers. Since we have no a priori hypothesis of a direction of effect for different 
CpG probes, and to avoid that positive and negative Z-statistics cancel out, we performed this 
test on the absolute value of the Z-statistic with the following weighting 
(2)	 𝑍!"#$%&'( = 𝑤!𝑍!!!!! 𝑤!!!!!!  
 
where 𝑤! = 𝑁! 
The right-tailed P-value of the joint test of no association was 2.18×10–11. As a robustness 
check we also performed this test while pruning the lead probes so that only the strongest 
association within 250kb was kept, and a right-tailed P-value of 4.91×10–6 based on 5 probes 
as the result. We interpret this as evidence that at least one probe has an estimated effect 
different from zero in the meta-analysis of the never smokers (however see Supplementary 
Note 4.4 for more discussion of maternal smoking as a confounding factor). 
4.3 Effect size comparison ever- versus never smokers 
We thereafter investigated the change in effect size estimates between the ever smokers and 
the never smokers. To be able to compare the differences in effect sizes and the precision of 
the estimates (SE), we used inverse-variance weighted meta-analysis to retain meta-analytical 
betas and standard errors for the 9 lead probes. We thereafter derived the effect sizes and 
standard errors of the ever smokers by assuming that the effect size estimates in the full 
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sample is a weighted average of the effect size estimates in the ever smokers and never 
smokers, as the two groups are mutually exclusive and the union between the two is the full 
EWAS sample.  
The result of the effect size comparison is presented in Figure 3. We aligned the effect sizes 
to the first quadrant by taking their absolute values so that all effect sizes were positive for 
the comparison. If the effect sizes would be similar across the subsamples we would expect 
them to align along the 45-degree line, and if confounding would be driving the effect size 
estimates then we would expect a cluster above the 45-degree line as the effect size estimates 
in the ever smokers would be greater than those in the never smokers. 
By visual inspection we observed a cluster of probes with larger effect size estimates in the 
ever smokers than in the never smokers (i.e., those above the 45 degree line). We also 
observed a second cluster of effect size estimates with similar estimates in both subsamples 
(i.e., those along the 45 degree line). The 2 lead probes that could potentially be associated in 
the never smokers i.e., cg12803068 and cg22132788, have slightly larger effect size 
estimates in the ever smokers than in the never smokers, however these larger estimates lie 
within the confidence intervals of the estimates in the ever smokers. The other 7 probes have 
effect size that are more than 50% smaller in the never smokers than in the ever smokers, and 
all of these effect size estimates are outside the confidence intervals of the estimates among 
ever smokers. 
4.4 Lookup of probes in EWAS meta-analysis on smoking and maternal 
smoking during pregnancy 
In Figure 3 and Supplementary Table S1.11 we present the effect-size estimates, in terms 
of R2, of the 44 probes of the adjusted model with P-value less than 1×10–5 (including the 9 
lead probes), ordered descendingly on R2, and in contrast we display these probes’ effect 
sizes when re-estimated in the never-smoker subsample, as well as the effect size of these 
probes as reported in the recent EWAS meta-analyses on smoking by Joehanes et al. (2016)6, 
and maternal smoking by Joubert et al. (2016)4. We report the effect sizes for smoking and 
maternal smoking if a probe was significantly associated in these studies at FDR < 0.05, as 
those results were publicly available.  
Noticeable is that the effect sizes of smoking and maternal smoking are many times larger for 
most probes compared to the effect of EA. Secondly, the probes cg12803068 and 
cg22132788 that were estimated with low P-values in the never smokers, and the closest 
gene; MYO1G, has been estimated as persistently affected by maternal smoking in new-
born’s as well as later in the life of the offspring4,38, and the effect of maternal smoking on 
these two probes is extreme; the R2s are respectively 8.34% and  and 6.33%. We have no 
possibility to control for maternal smoking and we can therefore not distinguish between the 
hypothesis that these probes have some true association with EA and the hypothesis that their 
apparent association with EA is entirely driven by more maternal smoking during pregnancy 
among lower-EA individuals. The extreme effect size of smoking and maternal smoking 
substantially weakens the possibility that these probes would be directly affected by EA, 
rather than indirectly by the confounding. We also cannot rule out that the probes’ association 
with EA is driven by second-hand smoke exposure, which could also be correlated with EA, 
and is not controlled for in regression. The lookup strongly suggests that smoking and 
maternal smoking remain potential confounding factors for the probe associations with EA, 
even in the subsample of individuals who are self-reported never-smokers. 
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5 Enrichment analyses 
5.1 Enrichment analysis of GWAS of smoking and EA 
We performed an enrichment analysis to investigate if the genetic loci, in proximity with the 
probes found to be associated in the adjusted EWAS model (at P < 1×10–4), also contain 
SNPs enriched for EA and smoking. For EA we used the GWAS summary-statistics from a 
large (n  = 405,073), recent meta-analysis by Okbay et al. (2016)34. For smoking we used a 
meta-analysis combining GWAS results from the UK Biobank together with the publically 
available summary statistics from the Tobacco, Alcohol, and Genetics Consortium (TAG, 
total n = 186,102)39, and this meta-analysis is described in detail in Karlsson Linnér et al. 
(Manuscript in preparation)40. 
The enrichment analysis was performed with the 179 EWAS probes from the adjusted model 
with P-value less than 1×10–4. We pruned the probes so that the probe with the lowest P-
value in a locus was selected as the lead probe, and all probes within 250kb from the lead 
probe was clumped with the strongest association. This resulted in 141 “approximately 
independent” lead probes (k). For each of the phenotypes, we extracted the closest SNP 
available in the GWAS summary statistics based on the physical position of the k lead 
probes. Using the reference panel 1000 Genomes phase 3 (October 2014 haplotype release 
version 5), we extracted the SNPs in strong LD (r2 >= 0.8) with the k SNPs, and then we 
averaged the absolute value of their Z-statistics of the association with the phenotype, as well 
as the minor allele frequency (MAF) of the SNPs in strong LD. This leads to a distribution of 
k average Z-statistics and average MAF. 
From the summary statistics we extracted a set of 1,000 random SNPs for each of the k SNPs, 
matched on the average MAF (+/- 1pp), and for the matched SNPs we also averaged the 
absolute value of the Z-statistics across the SNPs in strong LD, just as for the 141 “first-
stage” SNPs. This leads to a distribution of k×1,000 average absolute Z-statistics. We ordered 
the Z-statistics and performed a test of joint enrichment with the non-parametric Mann-
Whitney test of the null hypothesis that the association test statistic of the k SNPs are drawn 
from the same distribution as those of the 141,000 MAF-matched SNPs.  
5.1.1 Results – Enrichment analysis of GWAS of smoking and EA 
For EA, the average absolute value of the Z-statistics of the k SNPs is 1.199, the median 
0.956, and the average of the two-tailed P-values is 0.377. For the matched SNPs the average 
absolute value of the Z-statistics is 1.101, and the median is 0.889, and the average of the 
two-tailed P-values is 0.406. The result of the Mann-Whitney test does not reject the null 
hypothesis of no enrichment for EA (two-tailed P-value = 0.206). 
For smoking the average absolute value of the Z-statistics of the k SNPs is 0.953, the median 
0.846, and the average of the two-tailed P-values is 0.437. For the matched SNPs the average 
absolute value of the Z-statistics is 0.921, and the median is 0.760, and the average of the 
two-tailed P-values is 0.453. The result of the Mann-Whitney test does not reject the null 
hypothesis of no enrichment for smoking (two-tailed P-value = 0.504). 
5.1.2 Enrichment of individual SNPs 
We continued by examining if any of the average absolute Z-statistics of the 141 
“approximately independent” lead probes (k) were associated with the phenotypes. No loci 
were found to be associated with smoking (smallest two-tailed P-value = 0.001), while one 
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SNP, rs9956387, is associated with EA, two-tailed P-value of the average Z-statistic = 
4.39×10–8. The CpG probe related to the SNP, cg17939805, has P-value = 7.02×10–5 in the 
adjusted EWAS model results, and the distance between the probe and the SNP is 607 base 
pairs. 
5.2 Enrichment within methylation density regions (HIL) 
We clustered the meta-analysis results into the four methylation density categories (“HIL”) 
defined in Price et al., (2013)27, using the annotation file from that study. Each probe could 
be categorized as located in a high-density CpG island (HC), an intermediate-density CpG 
island (IC), a region of intermediate-density CpG island bordering HCs (ICshore), or a non-
island (LC). We investigated the enrichment for association of probes in these four 
categories. The results can be found in Supplementary Table S1.12. 
The number of probes with P < 10–7 is more or less proportional to the total number of probes 
in every category. The mean absolute Z-statistic is similar across categories, suggesting no 
difference in enrichment across categories. The enrichment statistic is defined as: 
(3)	 𝑍 = 1𝑆 𝑧!! − 1!!!!𝑠/𝑆  
where s indexes the number of probes, and 𝑧!! is the squared z-statistic from the regression of 
probe s on educational attainment (see also section 11 of the Supporting Information in 
Rietveld et al., 2014)41. This squared z-statistic captures the strength of the association 
between educational attainment and probe s, while ignoring the sign of the association. Under 
the null hypothesis, each 𝑧!~𝑁(0,1), and thus 𝑧!!~𝜒! 1 , which has mean 1 and variance 2. 
Therefore, under the null: 
(4)	 𝐸 𝑍 = 0, 𝑣𝑎𝑟 𝑍 = 1 𝑆 !𝑆𝑣𝑎𝑟(𝑍!!)2/𝑆 = 1 
We calculate a P-value for the test of whether the realized value of the test statistic, Z = z, 
differs from zero using the inverse cumulative distribution function of the standard normal 
distribution. The results indicate that there is enrichment for association in all four HIL 
categories. 
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6 Prediction of EA with polygenic methylation score 
To test the predictive accuracy of our EWAS findings we constructed polygenic methylation 
scores (PGMSs) to perform out-of-sample polygenic prediction of EA. The prediction was 
performed in three independent cohorts studies, the Lothian Birth Cohort 1936 (LBC1936, n 
= 917), Rotterdam Study BIOS (RS-BIOS, n = 671), and Rotterdam Study 3 (RS3, n = 729). 
For each of the prediction cohorts we created a new EWAS meta-analysis withholding the 
respective prediction cohort study to avoid overfitting42. The effect sizes (in terms of Z-
statistics) from the respective holdout meta-analysis were used as weights when constructing 
the PGMS. The Z-statistics were used instead of the EWAS coefficients because CpG 
methylation is the dependent variable in the EWAS regression. 
For each prediction sample we created four PGMS using two P-value thresholds P < 10–5 and 
P < 10–7, and the estimates from the basic and adjusted models. The PGMS was defined as 
the weighted sum of the Q CpG probes: 
(5)	 𝑀! = 𝑍!!!!! Β!"  , 
where 𝑀! denotes the methylation score of individual i, 𝑍! is the estimated Z-statistic for CpG 
probe j, and Β!" is the methylation beta-value for individual i at CpG probe j.  
A recent study showed that the phenotypic prediction can be improved if the PGMS is 
combined with a single-nucleotide polymorphism polygenic score (SNP PGS)43. We 
therefore included a SNP PGS constructed with the effect size estimates from a recent large-
scale GWAS on EA (n = 405,073)11, and the prediction cohorts were excluded from the 
GWAS meta-analysis to avoid overfitting. The SNP PGS was defined as the weighted sum of 
the T directly genotyped SNPs: 
(6)	 𝑆! = 𝛽!!!!! 𝑔!"  , 
where 𝑆! denotes the polygenic score of individual i, 𝛽! is the estimated additive effect size of 
the effect-coded allele at SNP 𝑗, and 𝑔!"  is the genotype of individual 𝑖 at SNP j (coded as 
having 0, 1 or 2 instances of the effect-coded allele)44. 
For each prediction cohort study we performed an OLS regression with EA as the dependent 
variable, and age and sex as control variables. The predictive power of the PGMS was 
evaluated as the incremental R2 of adding the PGMS to the regression model, i.e., the 
difference in R2 between the regression model with only the SNP PGS and the covariates, and 
the regression model with the PGMS together with the SNP PGS and the covariates. The 
incremental R2 of the interaction term (between the PGMS and SNP PGS) was evaluated as 
the difference in R2 between the regression model with the PGMS and the SNP PGS as 
additive main effects, together with the covariates, and the same regression model with the 
interaction term added. 
To estimate 95% confidence intervals for the incremental R2 we performed bootstraps with 
1,000 samples with the percentile interval method, and this was done with the ‘boot’ package 
in R9,45,46. Finally, the incremental R2 was meta-analysed across the three prediction cohorts 
(LBC, RS-BIOS, and RS3) as the sample-size weighted incremental R2. 
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6.1.1 ALSPAC prediction of educational achievement 
A further prediction analysis, using the same PGMS prediction method as described in 
Supplementary Note 6, was carried out in the ARIES substudy (n = 678) of the ALSPAC 
cohort47,38. Cord-blood methylation was assessed in newborn children and EA was measured 
using four sets of standardised Key Stage48 school grades from primary level through to high 
school (educational achievement was evaluated at ages 7-16 years), and the Key Stage 
educational achievement test scores are part of the state education system in the UK48. The 
cord blood signatures were collected prior to any educational exposure and may help identify 
if methylation differences might be a cause or consequence of EA. For each of the Key 
Stages 1 to 4, an average score across all school subjects was derived for each child. The 
predictive accuracy of the PGMS, built using the association Z-statistic from a meta-analysis 
excluding the ALSPAC cohort, was assessed as the incremental adjusted R2 of adding the 
score to the OLS regression model, with sex and age at assessment as control variables. 
Secondly, we tested if these associations were robust to the inclusion of maternal smoking as 
an additional control variable. Finally, we performed the prediction in a restricted sample 
using data from children of non-smokers only. 
6.2 Results – Prediction of EA with polygenic methylation score 
The result of the out-of-sample prediction with the polygenic methylation score (PGMS) is 
presented in Figure 5 and Supplementary Table S1.13a. The total meta-analysis sample 
size of the prediction across the three holdout-cohorts LBC1936, RS-BIOS, and RS3 was 
2,317. Based on the basic model parameter estimates and P-value threshold 1×10–5, the 
weighted average incremental R2 was 1.73%, and 1.80% with P-value threshold 1×10–7. 
The prediction results based on the adjusted model parameter estimates were consistent with 
those of the basic model. The weighted average incremental R2 was 2.00% at P < 1×10–5, and 
1.43% at P < 1×10–7. Notably, the predictive power at P < 1×10–7 was achieved with a PGMS 
of only 8 probes which could explain why the PGMS at P < 1×10–5 had greater explanatory 
power, even though this approach introduces more noise due to the inclusion probes that are 
less strongly associated with EA. 
6.2.1 Results – Interaction effect between PGMS and SNP PGS 
When the interaction between the PGMS and the SNP PGS was added to the model, the R2 
additionally increased in the range from 0.11% to 0.30% depending on the P-value threshold 
and EWAS weights. The interaction was generally significant at P < 0.05, except for the 
basic model at P < 1×10–5. This suggests that there is relatively weak evidence for an 
interaction between the PGMS and the SNP PGS in relation to EA. 
6.2.2 Results – Prediction in the never-smoker subsample 
Given our concerns that smoking is a confounding factor driving the associations between 
methylation and EA, we also considered the inclusion of an additional PGMS in the 
prediction. The additional PGMS was calculated with weights (Z-statistics) from an EWAS 
on smoking by Zeilinger et al. (2013)49, using the 187 probes that were identified at 
epigenome-wide significance (P < 1×10–7) and then successfully replicated. The smoking 
PGMS was created in three cohorts (RS3, RS-BIOS, LBC1936), and we calculated Pearson 
correlations between the PGMS of smoking and the PGMSs for EA constructed from the lead 
probes (i.e., those associated with EA at significance threshold P < 1×10–7) in either our basic 
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or adjusted model. All correlations were negative across all the EA PGMS, no matter if the 
scores were created with weights from the basic or adjusted model. That is, for the EA PGMS 
from our basic model, we find a correlation with the smoking PGMS of -0.96 in RS3, -0.94 in 
RS-BIOS, and -0.93 in LBC1936. For the EA PGMS from our adjusted model, the 
correlations are -0.90, -0.89, and -0.91, respectively. The correlations were in the expected 
direction, where increased EA is linked to less smoking. This strongly suggests that smoking 
status confounded the EWAS associations with EA. Because of strong multicollinearity we 
could not include the smoking PGMS to the prediction models. 
We also performed the prediction in the LBC1936, RS-BIOS, and RS3 cohorts in the 
subsample of never smokers with the four PGMSs constructed with the parameter estimates 
of the full EWAS sample. This subset had a total sample size of 876 individuals across the 
cohorts. The results are presented in Supplementary Table S1.13b. 
When the PGMS was constructed with probes estimated with P < 1×10–5, then the 
methylation score predicted 0.64% of EA with the basic model estimates (P = 0.018), and 
0.93% when constructed with the adjusted model effect sizes (P = 0.005). No PGMS was 
significant when constructed at P < 1×10–7. The marginal significance could be explained by 
the reduced power due to the smaller sample (876 never smokers compared to 2,317 
individuals in the full sample). No interaction effect between the PGMS and SNP PGS was 
found in the never-smoker subsample, as expected due to the reduced power. 
6.2.3 Description of the ALSPAC cohort 
ALSPAC50 recruited 14,541 pregnant women resident in Avon, UK with expected dates of 
delivery 1st April 1991 to 31st December 1992. 14,541 is the initial number of pregnancies 
for which the mother enrolled in the ALSPAC study and had either returned at least one 
questionnaire or attended a “Children in Focus” clinic by 19/07/99. Of these initial 
pregnancies, there was a total of 14,676 fetuses, resulting in 14,062 live births and 13,988 
children who were alive at 1 year of age.  
When the oldest children were approximately 7 years of age, an attempt was made to bolster 
the initial sample with eligible cases who had failed to join the study originally. As a result, 
when considering variables collected from the age of seven onwards (and potentially 
abstracted from obstetric notes) there are data available for more than the 14,541 pregnancies 
mentioned above. 
The number of new pregnancies not in the initial sample (known as Phase I enrolment) that 
are currently represented on the built files and reflecting enrolment status at the age of 18 is 
706 (452 and 254 recruited during Phases II and III respectively), resulting in an additional 
713 children being enrolled.  
The total sample size for analyses using any data collected after the age of seven is therefore 
15,247 pregnancies, resulting in 15,458 fetuses. Of this total sample of 15,458 fetuses, 14,775 
were live births and 14,701 were alive at 1 year of age.  
A 10% sample of the ALSPAC cohort, known as the Children in Focus (CiF) group, attended 
clinics at the University of Bristol at various time intervals between 4 to 61 months of age. 
The CiF group were chosen at random from the last 6 months of ALSPAC births (1,432 
families attended at least one clinic). Excluded were those mothers who had moved out of the 
area or were lost to follow-up, and those partaking in another study of infant development in 
Avon. 
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6.2.1 Results – ALSPAC prediction 
The only methylation score that reached nominal significance in the prediction of educational 
achievement test scores (Key Stage 1–4), was the prediction of Key Stage 4 with a PGMS 
constructed from probes with P < 1×10–7. The score explains 0.62% of the variance in school 
performance at Key Stage 4 (P = 0.024), and the age at assessment at this Key Stage is 15-16 
years. We present these results in Supplementary Table 1.13c. The predictive power 
attenuates completely upon adjustment for maternal smoking status, as well as in the sub-
group analysis of mothers who reported to have never smoked (incremental adjusted R2 = 
0.14%, P = 0.17). We draw two conclusions from these results from the child sample. First, 
they reinforce the concern that maternal smoking is a major confounding factor for all our 
probe associations with EA. Second, they suggest that any true methylation-EA associations 
are unlikely to be driven by a causal effect of methylation on EA. 
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7 Correlation of EWAS associations with tissue-specific 
methylation 
The NIH Roadmap Epigenomics Consortium recently made an impressive analysis and 
categorization of a multitude of different epigenetic marks, across 111 different tissues51. The 
data is publicly archived, and we harnessed their tissue-specific methylation data to answer 
the question of whether our EWAS associations are correlated with any tissue-specific DNA 
methylation. We hypothesize that EWAS associations for a given phenotype would be more 
likely to be located at loci that are differentially methylated in tissues relevant for the 
phenotype or endophenotypes. E.g., if our EWAS associations would be correlated with the 
tissue-specific methylation of brain tissues, that would increase the credibility of the 
associations, and improve the biological interpretation. 
Genome-wide methylation data was available for three kinds of CpG methylation 
measurements: whole-genome bisulfite sequencing (WGBS), reduced representation bisulfite 
sequencing (RRBS), and mCRF (a method combining sequencing data from the MeDIP-seq 
and MRE-seq methods). Methylation was measured as the beta value, ranging from 0 to 1, 
and it was available for 37 tissues measured with WGBS, 49 tissues with RRBS, and for 16 
tissues with mCRF. Only eight tissues were available for two or more methylation 
measurements. 
We pruned the probes of the adjusted EWAS model with P-value less than 1×10–4 using a 
window of 250kb, as described in 5.1 Enrichment analysis of GWAS of smoking and EA, 
which resulted in 141 “approximately independent” probes. Based on the physical location of 
the 141 pruned probes we extracted the beta-value for WGBS, RRBS, and mCRF. The beta-
values were first converted to M-valuese, and thereafter we calculated standardised tissue-
specific deviations (𝑍!"#,!) from the cross-tissue average methylation (𝑀𝑣𝑎𝑙!"#) for each of 
the 141 CpG loci as: 
(7) 𝑍!"#,! = 𝑀𝑣𝑎𝑙!"#,! −𝑀𝑣𝑎𝑙!"#𝑠.𝑑(𝑀𝑣𝑎𝑙!"#)  
where 𝑍!"#,! is the tissue-specific deviation for tissue t, at locus CpG. This procedure was 
performed within each methylation measurement. Hence, in the case that a tissue had no 
missing CpG loci, there were 141 tissue-specific deviations; each corresponding to one of the 
loci identified in the association results of the adjusted EWAS model. For RRBS, there were 
many missing values across all 49 tissues, and the maximum number of loci available was 38 
out of 141. We therefore excluded the RRBS measurement from further analysis, while both 
WGBS and mCRF had close to 141 overlapping loci for all tissues (Supplementary Table 
1.14). 
For WGBS and mCRF we calculated correlations with the tissue-specific Z-statistics and the 
EWAS association Z-statistics of the pruned probes (from the adjusted EWAS model). 
Bonferroni correction for the number of tissues within each methylation measurement was 
performed. 
                                                            
e As the consortium methylation data was only available with two decimals precision, we imputed 0’s and 1’s 
with 0.005 and 0.995 to avoid infinite M-values. 
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7.1 Results – Correlation of associations with tissue-specific methylation 
Genome-wide, the M-values were all highly positively correlated across the tissues, both for 
WGBS (r ranged between [0.728-0.967]) and mCRF (r ranged between [0.758-0.925]). The 
correlations of the standardised deviations were lower (ranging between [–0.253-0.498] for 
WGBS, and [–0.175-0.264] for mCRF). Hence, the level of methylation at each locus was 
very similar across the tissues, while the tissue-specific deviations (that can be both positive 
and negative) relative to the tissue average were less correlated, and some correlations were 
also negative for some tissue pairs, indicating an inverse relationship relative to the average 
cross-tissue methylation for these tissue pairs. 
The results of the correlations between the tissue-specific methylation and the Z-statistics of 
the pruned probes are reported in Supplementary Table 1.14 and Figure 6, and for some 
tissues there were significant correlations between the tissue-specific methylation and the 
EWAS associations.  
For WGBS, the correlations were in the range [–0.393, 0.509], and three correlations 
remained significant after Bonferroni-correction for the number of tissues (i.e., P < 0.05 / 37). 
The positive Bonferroni-significant correlations were primary haematopoietic stem cells G-
CSF-mobilized female (r = 0.509; Roadmap ID E050, category: haematopoietic stem cells), 
and thymus (r = 0.381; Roadmap ID E112, category: Thymus). The negative Bonferroni-
significant correlation was IMR90 fetal lung fibroblast (r = –0.393; Roadmap ID E017, 
category: IMR90). It should be noted that the primary haematopoietic stem cells G-CSF-
mobilized tissue was not available in a male sample. 
There were six WGBS correlations that reached marginal significance (P < 0.05): right 
ventricle (r = 0.19; Roadmap ID E105, category: Heart), ES-UCSF4 cells (r = 0.185; 
Roadmap ID E024, category: Embryonic stem cell), and the negative correlations were 
oesophagus (r = –0.234; Roadmap ID E079, category: Digestive), HUES64 derived CD56+ 
mesoderm (r = –0.195; Roadmap ID E013, category: Embryonic stem cell derivatives), small 
intestine (r = –0.194; Roadmap ID E109, category: Digestive), and HUES64 derived 
CD184+ endoderm (r = –0.194; Roadmap ID E011, category: Embryonic stem cell 
derivatives). 
The correlations with the mCRF methylation measurements were in the range [–0.234, 
0.162], and there were no Bonferroni-significant correlations (i.e., P < 0.05 / 16). There was 
one negative correlation with P < 0.05: the tissue Breast vHMEC mammary epithelial (r = –
0.234; Roadmap ID E028, category: Epithelial). 
There are two tissues categorized as brain tissues in the WGBS methylation data, brain 
germinal matrix (r = 0.044, Roadmap ID E070, P-value = 0.607) and brain hippocampus 
middle (r = 0.115, Roadmap ID E071, P-value = 0.175). The absolute correlation of brain 
hippocampus middle is just above the average of the absolute correlations (|𝑟|=0.105) across 
the 37 WGBS tissues, and we therefore do not interpret this as evidence in favor of 
differential methylation in brain tissues (i.e., a plausible endophenotype of EA) at the CpG 
loci found in the EWAS, compared to the other tissues. 
The mCRF data contains two brain tissues, fetal male brain (r = 0.162, Roadmap ID E081, P-
value = 0.057), and fetal female brain (r = 0.037, Roadmap ID E082, P-value = 0.66), and the 
fetal male brain correlation is the second largest absolute correlation found for the mCRF 
measurement, with a P-value close to marginal significance. However, the correlation is not 
as strong as the other correlations found with WGBS, and it is inconsistent with the 
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correlation in fetal female brain. We therefore did not interpret this in favor of our EWAS 
findings being correlated to differential methylation in brain. 
The strongest correlations were found for haematopoietic stem cells (r = 0.509), which is the 
direct source of all other blood cells, and for fetal lung fibroblasts (r = –0.393). In general, 
the significant correlations are hard to interpret as they are spread across multiple cell types 
and tissues. We interpret the lack of correlation with tissues plausibly related to EA (such as 
brain tissues) as supporting the hypothesis that the EWAS results are driven by confounding 
factors rather than by a true association with EA. 
As a robustness check we performed the above analysis while pruning the probes with P-
value less than 1×10–2 instead of 1×10–4, and the correlations were stable when compared 
across the P-value thresholds. However, when the analysis was performed with all ~450,000 
probes, then the correlations attenuated to ~0 for all tissues. We think that including more 
probes increases the power until too many non-associated probes are included in the 
correlation, and the non-associated probes attenuate the correlations towards zero past some 
optimal P-value threshold with optimal signal-to-noise ratio. 
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8 Expression analysis 
Using the GTEx expression data52 and the webtool ‘Functional mapping and annotation of 
genetic associations’ (FUMA)53, we clustered the expression of the 29 genes physically 
closest to the CpG probes of the adjusted model (with P < 1×10–5). Normalization of Reads 
Per Kilo base per Million (RPKM) was performed as zero-mean normalization with a log2 
transformation of the RPKM, with pseudocount 1, and it was performed per gene. Average 
normalized expression values were computed per 53 specific tissue types. Genes and tissues 
were clustered by hierarchical clustering using pairwise Euclidian distance. 
The result of the expression analysis is displayed in Supplementary Figure 4. By visual 
examination we observed one noticeable cluster of 10 genesf where each gene individually is 
more highly expressed in the brain tissues compared to all other tissues. This set of genes 
could possibly be related to EA due to the cognitive nature of the phenotype, however we 
interpret this as merely suggestive evidence, and the gene sets (containing 10 and 29 genes) 
are too small for a well-powered test for differential brain tissue expression. A second cluster 
of 19 genesg was observed that are more highly expressed in a wide variety of tissues 
including spleen, lung, thyroid, among many others, than compared to the brain tissues. 
Tentatively, one could expect this pattern if the genes are involved in the toxicological 
adverse effects of smoking in different tissues. Overall, the expression analysis did not 
support the hypothesis that our EWAS findings are immediately related to brain function or 
cognition. 
                                                            
f The genes that form a cluster with higher expression in brain tissues, compared to all other tissues, are KCNH3, 
CLSTN1, YWHAQ, LINC00277, C10orf107, RNF220, MKRN3, GAL3ST3, PFZD7, and FLRT1. 
g The genes that form a cluster with higher expression in a wide variety of tissues, compared to the brain tissues, 
are DAPL1, WT1, MYO15B, MYO1G, STK40, ASCL2, AHRR, DOT1L, SSR3, POLK, SP3, ARID1B, ZNF267, 
ZNF808, C1D, EXOC2, F2RL3, CDCP1, and IER3. 
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9 methQTL analysis 
It has been shown that genetic variants also explain variation in CpG levels1 in addition to 
environmental influences on DNA methylation. EWAS probes under genetic influence may 
help us understand the direction of association between CpGs and outcomes, but it can also 
be a confounding factor. SNPs affecting the level of methylation, usually referred to as 
methylation quantitative trait loci (methQTL)1, sometimes have effect sizes that can be found 
in samples of less than a thousand individuals54,55, which is much less than what is necessary 
for most GWAS of e.g. behavioral phenotypes34. Therefore, as is customary in the EWAS 
literature, we performed a GWAS for each of the 9 lead probes to investigate if any SNPs 
were associated with the level of methylation. The genome-wide association analysis was 
performed in the LBC1936 (n = 918) and RS3 (n = 731) cohorts that estimated the following 
GWAS regression equation for each autosomal bi-allelic SNP and lead probe: 
(8) 𝑌! = 𝛽! + 𝛽!𝑆𝑁𝑃! + 𝑷𝑪𝒊𝜸+ 𝑿𝒊𝜶+ 𝑪𝒊𝜽+ 𝜖! , 
where 𝑌! is the methylation beta-value for individual 𝑖, 𝑆𝑁𝑃! is the number of reference 
alleles of the SNP, 𝑷𝑪𝒊 is a vector of the first four principal components of the genetic 
relatedness matrix, and 𝑿𝒊 is a vector of the control variables age and sex, as well as an 
interaction term between age and sex. 𝑪𝒊 is a vector containing study-specific controls and 
technical covariates (such as dummy variables for genotyping array and genotyping batches). 
9.1 Quality control of methQTL analyses 
The GWAS results of the methQTL analyses were quality controlled according to a stringent 
protocol by the GIANT consortium56, and the protocol was implemented with the EasyQC 
software. In summary the following major filters were applied; removal of monomorphic and 
multi-allelic SNPs, and structural variants such as INDELs; removal of SNPs with an 
IMPUTE imputation quality < 0.7; and of SNPs with a minor allele frequency (MAF) < 0.05. 
The quality control procedure ensures that all SNPs have alleles aligned to the 1000G phase 
3, version 5 (October 2014 haplotype release)57, and SNPs that could not be aligned with the 
reference were removed. 
9.2 Results – methQTL analysis 
Using the software METAL29 we performed sample-size weighted meta-analysis across the 
LBC1936 and RS3 cohorts with a total sample size of 1,649. The meta-analysis resulted in no 
genome-wide significant (P < 5×10–8) methQTLs for any of the 9 lead probes. We note that 
the non-significant results could be the result of the relatively small sample size of the meta-
analysis, although the current sample size has 80% statistical power to find SNP-effects with 
R2 = 2.37% at genome-wide significance. To put these effect sizes into perspective, previous 
studies find many CpG loci where the variance of the methylation level is explained by up to 
89% by SNP effects (Gibbs et al., 2010; Lemire et al., 2015)55,58. The observed effect sizes in 
our methQTL analyses are much smaller (< 2%), and we therefore belive that the magnitude 
of the possible confounding for the 9 lead probes due to SNP-effects is low compared to 
SNP-effects observed for other CpGs (that are not associated in our EWAS). 
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13 Supplementary figures 
Supplementary Figure 1 – Manhattan plots of the basic and adjusted EWAS models. 
Manhattan plots of the EWAS meta-analysis of EA from (a) the basic model, and (b) the 
adjusted model. The x-axis is chromosomal position, and the y-axis is the significance on a 
−log10 scale. The dashed line marks the threshold for epigenome-wide significance (P = 
1×10–7). Each epigenome-wide significant association is marked with a red ×.  
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Supplementary Figure 2 – QQ plots of the basic and adjusted EWAS models. Quantile-
quantile (QQ) plots of the EWAS meta-analysis of EA for (a) the basic model and (b) the 
adjusted model. The gray shaded areas in the QQ plots represent the 95% confidence 
intervals under the null hypothesis. The presented genomic inflation factor, 𝜆!" , is calculated 
after probe filtering and cohort-level genomic control. 
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Supplementary Figure 3 – The effect size comparison between ever smokers and never 
smokers. Effect size estimates with 95% confidence intervals in the ever smokers plotted 
against the effect size estimates in the never smokers. Panel (a) displays the effect size 
estimates from the meta-analysis of the re-estimation in the never-smoker subsample (N = 
5,175) for the basic model, and panel (b) displays the comparison for the adjusted model. We 
aligned the effect sizes to the first quadrant by taking their absolute values. The line 
represents the 45-degree line. The two probes discussed in Supplementary Note 2.3.3; 
cg12803068 and cg22132788, are marked in the figure. 
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Supplementary Figure 4 – Heatmap of the expression analysis using GTEx expression data. The heatmap created with the webtool FUMA53, displays the normalised 
expression for the 29 genes in proximity with the CpG probes with P-value < 1×10–5 of the adjusted EWAS model.  The color spectrum represents the normalized relative 
expression across tissues per gene (Reads Per Kilo base per Million, RPKM). Two clusters were observed and these are marked by red lines, the first cluster consists of the 10 
genes – KCNH3, CLSTN1, YWHAQ, LINC00277, C10orf107, RNF220, MKRN3, GAL3ST3, PFZD7, and FLRT1, and this cluster is observed as more highly expressed in 
brain tissues compared to the other tissues. The cluster is located between “Brain_Spinal_cord_cervical_c-1” and “Brain_Nucleus_accumbens_basal_ganglia” in the top-mid 
part of the heatmap. The 19 genes DAPL1, WT1, MYO15B, MYO1G, STK40, ASCL2, AHRR, DOT1L, SSR3, POLK, SP3, ARID1B, ZNF267, ZNF808, C1D, EXOC2, F2RL3, 
CDCP1, and IER3, form a second cluster of genes that are more highly expressed in a wide variety of non-brain tissues compared to the brain tissues. The second cluster is 
located in the bottom-left corner between “Cells_EBV-transformed_lymphocytes” and “Uterus”. The method is described in Supplementary Note 8. 
